Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930303 | 0.79 | HIF1A (0.42) | HIF1AEPAS1 | |
| SCHEMBL15052201 | 0.77 | HIF1A (0.53) | ALDH1A1HIF1AEPAS1HRH3POLB | |
| SCHEMBL2564150 | 0.76 | HIF1A (0.49) | KDM4EHIF1AEPAS1KCNH2USP2 | |
| SCHEMBL15052336 | 0.74 | HIF1A (0.53) | ALDH1A1HIF1AEPAS1HRH3CYP2D6 | |
| SCHEMBL15052753 | 0.71 | HIF1A (0.55) | HIF1AEPAS1CYP2D6 | |
| SCHEMBL2562807 | 0.70 | KDM4E (0.34) | ALDH1A1KDM4EHIF1AEPAS1HRH3 | |
| SCHEMBL8117447 | 0.66 | HIF1A (0.36) | ALDH1A1KDM4EHIF1AEPAS1POLB | |
| SCHEMBL26944372 | 0.64 | HRH3 (0.57) | ALDH1A1KDM4EHRH3TSHRKCNH2 | |
| SCHEMBL30814161 | 0.61 | HIF1A (0.48) | HIF1AEPAS1KCNH2 | |
| SCHEMBL2584901 | 0.61 | POLB (0.58) | ALDH1A1KDM4EHRH3PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | ALDH1A1 324/4885KDM4E 2317/4885HIF1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.